WHO Raises Ethical Concerns Over Guinea-Bissau Vaccine Trial
Analysis based on 15 articles · First reported Feb 13, 2026 · Last updated Feb 16, 2026
The event highlights ethical considerations in medical research, potentially influencing funding and regulatory scrutiny for pharmaceutical and biotechnology companies involved in vaccine development and trials. It underscores the importance of established public health interventions like the Hepatitis B vaccine.
The World Health Organization has raised significant ethical and scientific concerns regarding a proposed randomized controlled trial in Guinea-Bissau. The trial aimed to assess broader health effects of the hepatitis B birth dose vaccine but involved withholding the proven life-saving intervention from some newborns, which the World Health Organization deemed inconsistent with core ethical standards. The hepatitis B birth dose vaccine prevents 70-95% of mother-to-child transmission and is crucial for global hepatitis elimination. Guinea-Bissau, which has a high burden of hepatitis B, has suspended the study pending further technical review. The United States===Centers for Disease Control and Prevention initially funded the $1.6 million study. Conflicting reports emerged regarding the study's status, with one official stating it was canceled while another indicated it was proceeding. Guinea-Bissau has committed to adding the hepatitis B birth dose to its national immunization program by 2028.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard